Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition